Japan-based Astellas Pharma has acquired British gene therapy company Quethera, which primarily develops new treatments for ocular diseases such as glaucoma.

Under a purchase agreement, Astellas is set to pay a total consideration of approximately £85m ($108.5m) for Quethera, including upfront and contingents.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The deal adds Quethera’s ophthalmic gene therapy programme to Astellas’ portfolio.

This pre-clinical candidate leverages a recombinant adeno-associated viral vector system (rAAV) to deliver therapeutic genes into target retinal cells to treat glaucoma.

In pre-clinical models, the therapy is said to have resulted in significantly improved survival of retinal ganglion cells (RGCs).

Astellas expects the therapy to help in addressing refractory glaucoma without the requirement for intraocular pressure (IOP).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“We believe the rAAV programme has potential as a new therapeutic option for the treatment of refractory glaucoma.”

Astellas president and CEO Kenji Yasukawa said: “We believe the rAAV programme has potential as a new therapeutic option for the treatment of refractory glaucoma through an intraocular pressure (IOP)-independent mechanism.

“It would address a high unmet medical need in glaucoma patients who are at risk of losing their eyesight.”

Quethera will become a wholly owned subsidiary of Astellas after the completion of the transaction.

Quethera CEO Peter Widdowson said: “Quethera’s novel technology approach is focused on exploring potential treatment options for common ophthalmic diseases, such as glaucoma, that can cause blindness and severely affect the quality of life for patients.

“This deal enables us to accelerate our evaluation of this investigational technology programme to see if we can slow or prevent disease progression for these patients.”

Founded in 2013, Quethera has been backed by UK Innovation and Science Seed Fund (UKI2S) with co-investment from Cambridge Enterprise.